Resource Summary Report

Generated by NIF on Sep 19, 2026

769-P

RRID:CVCL_1050
Type: Cell Line

Proper Citation

KCB Cat# KCB 2013031YJ, RRID:CVCL_1050

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1050

Proper Citation: KCB Cat# KCB 2013031YJ, RRID:CVCL_1050

Description: Cell line 769-P is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Renal cell carcinoma

Defining Citation: PMID:721102, PMID:1010528, PMID:6244232, PMID:17178751, PMID:20215515, PMID:22185343, PMID:22460905, PMID:22949125, PMID:25485619, PMID:25877200, PMID:26589293, PMID:27397505, PMID:27993170, PMID:28196595, PMID:28489074, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: 769-P

Synonyms: 769P, 769-p

Cross References: BTO:BTO_0006376, CLO:CLO_0001485, EFO:EFO_0002099, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1933, BioGRID_ORCS_Cell_line:501, BioSample:SAMN03473275, BioSample:SAMN10988198, cancercelllines:CVCL_1050, CCRID:1101HUM-PUMC000333,

CCRID:3101HUMSCSP5060, CCRID:3101HUMTCHu215, CCRID:4201HUM-CCTCC00103, CCTCC:GDC0103, Cell_Model_Passport:SIDM00803, ChEMBL-Cells:CHEMBL3308705, ChEMBL-Targets:CHEMBL1075385, CLS:300106, Cosmic:687935, Cosmic:801355, Cosmic:910922, Cosmic:982280, Cosmic:1779197, Cosmic:2520640, Cosmic-CLP:910922, DepMap:ACH-000411, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:910922, GEO:GSM374479, GEO:GSM827256, GEO:GSM886844, GEO:GSM887908, GEO:GSM1669571, IARC_TP53:21154, IGRhCellID:769P, IZSLER:BS TCL 123, KCB:KCB 2013031YJ, LiGeA:CCLE_445, LINCS_LDP:LCL-1772, PharmacoDB:769P_27_2019, PRIDE:PXD030304, Progenetix:CVCL_1050, PubChem_Cell_line:CVCL_1050, Wikidata:Q54604830

ID: CVCL_1050

Vendor: KCB

Catalog Number: KCB 2013031YJ

Record Creation Time: 20220427T215059+0000

Record Last Update: 20260913T011842+0000

Ratings and Alerts

No rating or validation information has been found for 769-P.

No alerts have been found for 769-P.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 200 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Molotkova A, et al. (2026) ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis. Cancer research communications, 6(3), 477.

Wang J, et al. (2026) Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma. Cancer research, 86(9), 2237.

Abou Alaiwi S, et al. (2026) Generation of a comprehensive epigenomic atlas in clear cell renal cell carcinoma informs kidney cancer progression and heritability. Cell reports, 45(2), 116968.

Hatayama T, et al. (2026) Nectin-4 drives aggressive tumor biology and poor prognosis in renal cell carcinoma. Urologic oncology, 44(8), 108.

Gu S, et al. (2026) MAGI3 deficiency unleashes ??-catenin conformational change to drive metastatic progression and mTOR inhibitor resistance in ccRCC. Cell death & disease, 17(1).

Liu Y, et al. (2026) Mitofusin-2 suppresses tumor immune escape through EGFR/STAT3-mediated PD-L1 transcription. Cell death & disease, 17(1).

Chen Y, et al. (2026) USP15 stabilizes c-Myc to drive sunitinib resistance by suppressing cuproptosis in clear cell renal cell carcinoma. Cell reports, 45(5), 117328.

Liao C, et al. (2026) Selective degradation of TBK1 uncovers mechanistic insights into blocking ccRCC progression. Cell chemical biology, 33(4), 461.

Yang T, et al. (2026) Molecular Glue cc-885 Inhibits VHL-Deficient Clear Cell Renal Cell Carcinoma via ETS1 Degradation. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(42), e20237.

Lu Z, et al. (2025) Integrated single-cell and bulk transcriptome analysis revealed high plasticity subpopulation and promising diagnosis model for clear cell renal cell carcinoma. Hereditas, 162(1), 198.

Qu Y, et al. (2025) Proteogenomic Analysis Identifies Clinically Relevant Subgroups of Collecting Duct Carcinoma. Research (Washington, D.C.), 8, 0859.

Zhang Q, et al. (2025) The extracellular-matrix-remodeling capability exposes therapeutic vulnerability in a subset of renal cell carcinomas with tumor thrombi. Developmental cell.

Luo J, et al. (2025) Machine learning-derived natural killer cell signature predicts prognosis and therapeutic response in clear cell renal cell carcinoma. Translational oncology, 51, 102180.

Jiang Q, et al. (2025) HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy. Cell, 188(7), 1807.

Johnson M, et al. (2025) Loss of SETD2 in wild-type VHL clear cell renal cell carcinoma sensitizes cells to STF-62247 and leads to DNA damage, cell cycle arrest, and cell death characteristic of pyroptosis. Molecular oncology, 19(4), 1244.

Zhu T, et al. (2025) Identification of IGF2BP3 and CENPA as key regulators of immunophenotypes in renal clear cell carcinoma. Frontiers in genetics, 16, 1749780.

Ye W, et al. (2025) TCIRG1 as a Novel Prognostic Biomarker Triggering Immune Infiltration in Renal Clear Cell Carcinoma: An Integrative Study of Single-Cell and Bulk Data. Human mutation, 2025, 1839494.

Shirole NH, et al. (2025) Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer. Cancer discovery, 15(7), 1484.

Takai Y, et al. (2025) Ankrd1 Promotes Lamellipodia Formation and Cell Motility via Interaction with Talin-1 in Clear Cell Renal Cell Carcinoma. International journal of

molecular sciences, 26(9).

Hase N, et al. (2025) APOBEC3C-mediated NF-??B activation enhances clear cell renal cell carcinoma progression. Molecular oncology, 19(1), 114.